| Outcome Measures: |
Primary: Number of Participants Reporting Adverse Events, Baseline through Week 14|Number of Participants with Clinically Significant Change From Baseline in Laboratory Abnormalities, Baseline through Week 14|Number of Participants With Clinically Significant Change From Baseline in Vital Signs, Baseline through Week 14|Number of Participants With Clinically Significant Change From Baseline in 12-Lead ECGs, Baseline through Week 14|Number of Participants with categorical scores on the Columbia Suicide Severity Rating Scale (C-SSRS), Baseline through Week 14 | Secondary: Maximum Observed Plasma Concentration (Cmax), Part A: Days -1, 1, 14, 21 & 28. Days 2, 4, 7, 10, 17, 20, 24, 30. Part A & B: Days -1, 1, 28, 49 & 56. Days 7, 14, 21, 35, 42, 57 & 58. Part C: Period 3 Day 3 & Period 5 Day 28|Area Under the Curve from Time Zero to end of dosing interval (AUCtau), Part A: Days -1, 1, 14, 21 & 28. Days 2, 4, 7, 10, 17, 20, 24, 30. Part A & B: Days -1, 1, 28, 49 & 56. Days 7, 14, 21, 35, 42, 57, 58. Part C: Period 3 Day 3 & Period 5 Day 28|Time to Reach Maximum Observed Plasma Concentration (Tmax), Part A: Days -1, 1, 14, 21 & 28. Days 2, 4, 7, 10, 17, 20, 24 & 30. Part A & B: Day -1, 1 28, 49 & 56. Days 7, 14, 21, 35, 42, 57 & 58. Part C: Period 3 Day 3 & Period 5 Day 28|Plasma Decay Half-Life (t1/2), Part A: Day -1, 1,14, 21 & 28. Days 2, 4, 7, 10, 17, 20, 24 & 30. Part A & B: Day -1, 1, 28, 49 & 56. Days 7, 14, 21, 35, 42, 57 & 58. Part C: Period 3 Day 3 & Period 5 Day 28|Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau), Part A: Day 28. Part A & B: Day 56|Percentage of Dose of PF-06751979 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%), Part A: Day 28. Part A & B: Day 56|Renal Clearance (CLr), Part A: Day 28. Part A & B: Day 56
|
